Clinical Trial Update: A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating bemcentinib in combination with erlotinib in non-small cell lung cancer has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bemcentinib (bemcentinib)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: BerGenBio ASA | Conditions: Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-02-26